Neurological Biomarkers Market

Neurological Biomarkers Market Outlook (2023 to 2033)

The global neurological biomarkers market is estimated to reach a valuation of US$ 8 billion in 2023. As per Future Market Insights (FMI) analysis, the neurological biomarkers market size is expected to surpass US$ 12.5 billion in the next decade. Between 2023 and 2033, the market has been forecast to register a 4.6% CAGR.

In their healthcare business, key players have a central platform for storing, managing, and analyzing biomarker and multi-omics data. The Human Genome Project's emergence provided researchers with new molecular tools for gene identification and gene expression. It allowed researchers to detect genetic flaws linked to complicated disorders, including common neurological ailments, ushering in a new era of study.

Customized antibodies and assays are developed by key players to measure unique clinical biomarkers in a wide range of neurodegenerative disorders and conditions, including Alzheimer's disease, Parkinson's disease, and traumatic brain injury. Their tests allow for early identification of symptoms before they arise, delivering vital information from the medication research phase to clinical practice, therefore improving the lives of patients. This development is expected to boost the market further.

For instance, the 'TaqMan Gene Expression Assays enable researchers to employ real-time PCR to analyze how gene expression changes in samples collected from a person suffering from a complicated ailment. Furthermore, TaqMan Assays can be used in in-vitro investigations that focus on a specific genetic or environmental component that is hypothesized to be implicated in complex disease.

Cerebrospinal Fluid (CSF) biomarkers and neurofilament proteins, according to experts, should be stable during long-term preservation. However, there are few studies and some evidence that freezing and thawing might cause structural alterations in CSF samples. Increasing CSF sample storage might result in experimental data that can be used to solve this topic. Such studies provide opportunities for market players and act as propellers for the market.

All of the research conducted by significant firms is evidence-based, and patients are managed using a test based on facts rather than subjective interpretation. Furthermore, they strive for safe therapies by limiting needless CT scan radiation exposure. Most key players have extensive experience in executing and cooperating on clinical research. They feel that collaboration is critical in developing novel biomarkers and therapies for the brain. Hence, key players engage in collaborative work and aid the market.

Moreover, they also allow their customers to collaborate by contacting them to handle brain damage and neurological illnesses. In addition, they provide access to a constantly expanding library of thousands of highly-curated disease-relevant experiments, including immunological, neurological, metabolic, and cardiovascular illnesses, with a special focus on expression studies, to speed predictive biomarkers and therapeutic target development, thus helping market growth.

A Contrast with the Historical Market Scenario

The statistics accumulated by Future Market Insights reveal the global forum of neurological biomarkers, which has witnessed an unprecedented surge over the past few years. The key providers in the market are in conjunction with the increasing demand for neurological biomarkers. There has been a gradual rise from a CAGR of 5.2% registered during the period of 2017 to 2022 and is likely to decrease at an adequate 4.6% in the forecast period.

Complications in the basic understanding of the molecular signatures of biological processes, as well as the neglect of treatment of neurological disorders, may slightly decline the market growth during the forecast period. On the contrary, spreading awareness regarding the benefits of predictive biomarkers may create several market opportunities for key clinicians.

Category-wise Insights

Alzheimer's Disease - By Application Type

By application type, the market is segmented into Alzheimer's disease, Parkinson's disease, Huntington's disease, schizophrenia, depression, multiple sclerosis, and spinal muscular atrophy. It has been studied by the analysts at Future Market Insights that the Alzheimer's disease segment is estimated to hold a major market share of 5.2% through the forecast period.

The vital elements determining the momentum of this segment are:

• The increasing disease burden and the availability of clinically useful goods, such as imaging biomarkers-amyloid PET tracers for diagnosis, are attributed to the growth of the segment.
• The government and non-profit organizations are offering several research possibilities that might boost segment growth.

Pharma & Biotech Companies - By End User Type

By end-user type, the market is segmented into research organizations, pharma & biotech companies, and clinical diagnostics. It has been studied by the analysts at Future Market Insights that the pharma & biotech companies segment is estimated to hold the largest market share through the forecast period.

• The pivotal aspects determining the momentum of this segment are:
• The growth of this segment is owing to the rising use of biomarkers in medication discovery and development by pharmaceutical firms and ambulatory surgery centers (ASCs).
• Key clinicians are involved in different Research and Development (R&D) activities in the field of biomarkers that contribute to the considerable share of this segment.

Crucial Position of Neuropathologists & Other Drivers

Recent biomarker breakthroughs, such as biomarker signatures, are making neurological illnesses more curable. As a result, non-invasive diagnostics, faster medication development, and earlier diagnosis are now possible. In addition, key players are conducting clinical trials and biomarker research and development (R&D) to provide more precise findings for neurological illnesses, which is likely to increase demand for neurological biomarkers throughout the projected period.

The need for verifying and finding biomarkers in big populations is enormous. This strategy is being used in the research process, which increases the likelihood of the neurological biomarkers market growing rapidly in the next years. Furthermore, neuropathologists are expected to determine the nomination and delineation of suitable treatment regimens as new and fresh neuroscience biomarkers are introduced.

Precision medicine, also known as customized medicine, has been identified as one of the most promising techniques for treating a variety of disorders. The increasing frequency of the brain and other nervous system tumors is one of the primary reasons driving the market growth. It is becoming more used as a diagnostic technique, assisting in the identification of certain biological markers.

Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

Region-wise Analysis

Presence of Well-known Neurological Specialists in the USA Involved in Extensive Research

North America is one of the leading neurological biomarkers markets. The USA is the most lucrative market in the region, with a revenue share of 3.9%. The value of the smart home devices market in the USA is estimated to reach a high of US$ 3.9 billion by the year 2033. The dominance of the country is attributed in part to its relatively high illness burden, adoption of biomarkers for diagnostic, therapeutic development, and prognostic reasons, and a boost in research funding.

The global cost of dementia was $818 billion in 2015, and it is anticipated to reach $2 Tn by 2030, according to the WHO. Key stakeholders in the United States are delivering an interactive teaching course that includes insights from world-renowned specialists on the clinical utility of standardized CSF testing to enable a fast diagnosis of Alzheimer's disease.

To speed clinical development projects, top scientists and industry-leading laboratories drive the creation of more advanced biomarker strategies, as well as specialized tests and on-target protocol assistance. Furthermore, prominent doctors claim to have extensive neurodegeneration biomarker experience to assist in making decisions. They have a strategic focus on neurodegeneration, neuroinflammation, traumatic brain injuries (TBI), and multiple sclerosis (M.S.), and they collaborate with a fast-developing network of university researchers, pharmaceutical, and biotech partners to enhance head health research.

In Germany, Key Clinicians are Using AI to Produce Predictive Biomarkers on Neural Network Activity!

Germany is a market with several market opportunities and a favorable revenue share. Key players in Germany provide research facilities that target all aspects of neurodegenerative illnesses (such as Alzheimer's, Parkinson's, and Amyotrophic lateral sclerosis) in order to create innovative preventive, treatment, and healthcare techniques. On a national and global scale, they work closely with universities, university hospitals, and other research institutes.

Key players strive to produce so-called functional biomarkers based on neural network activity utilizing artificial intelligence and unique mathematical techniques. These biomarkers are supposed to disclose whether the network is functioning properly or not, as well as if a certain medicine changes this state, which ultimately assists in the identification of potential drugs. Moreover, driven by a passion for promoting human health for all, they are establishing a network of discovery, connecting scientists, and exchanging thoughts, ideas, and knowledge in order to advance neuroscience research.

Japan: A Country with A Higher Geriatric Population, Possibly Suffering from Neurological Ailments

The Asia Pacific currently holds a notable share of the neurological biomarkers market, with Japan and India as its most lucrative markets. This is attributed to a growing number of clinical studies being done in developing nations such as India and China, as well as rising illness rates and growing demand for targeted therapies in the central nervous system, which are projected to fuel the biomarkers market.

Japan holds a revenue share of 5.3%, with an approximated valuation of US$ 643.8 million by 2033. The country has a strong position in the neuroimaging market, owing to the launch of unique solutions such as PET scanners with motion correction and the development of new IVD tests, which are expected to catalyze the growth of the medical device industry in the country.

Japan is a country with a high number of elderly people. As the geriatric population grows, it is expected that the number of patients suffering from neurodegenerative disorders may grow as well. As the chance of getting various diseases grows with age, numerous biomarkers that could be used to evaluate diseases are being developed. These biomarkers can detect the presence of diseases as well as track their progression and treatment success.

Key Players in India are Bringing Breakthrough Discoveries in Neurological Disorders

India is currently the largest neurological biomarkers market and holds a high revenue share of 6.1%, with an approximated valuation of US$ 354 million by 2033. In India, key players strive to alter the future of healthcare by using ultrasensitive biomarker detection. A certain market player has a team of empowered researchers that use their ‘Simoa’ precision tools, diverse menu of assay kits, and bespoke assay creation services to bring breakthrough discoveries in illness and therapy to the forefront.

The digital health solutions offered by regional players enable the development of methodologies that provide illness diagnosis far earlier, improved prognoses, and enhanced treatment ways to improve the population's quality of life and lifespan for future generations.

Newcomers are Catching Up with Key Players with Innovative Strategies: Start-up Sphere

Start-up companies are offering additional therapeutic solutions, as well as advanced technology to provide ample biomarkers in neurological disorders:

• SpinTech - It creates software for brain imaging. The firm provides MRI processing software that reduces the time required for full brain image capture. It also aids in the visualization, measurement, and identification of neurological biomarkers. Furthermore, it focuses on the diagnosis and treatment of TBI, dementia, stroke, and Parkinson's disease. SPIN-SWI, their flagship platform, provides 3D gradient-echo brain imaging, and SPIN-STAGE, their other platform, provides multi-contrast gradient-echo images.
• Altoida - It offers an AI-powered tool for forecasting the development of Alzheimer's disease. The business has created activities that provide neuromotor biomarkers, which they believe may be used to diagnose Alzheimer's disease.
• Valted Seq - It creates therapeutic treatments and biomarkers for the treatment of neurodegenerative illnesses. Using single-cell sequencing data, the business is developing precision treatments and new biomarkers for a variety of neurological illnesses, including Alzheimer's and Parkinson's.

Key Companies Transforming the Neurological Biomarkers Market Space

The presence of a considerable number of key companies in several regions is contributing to market growth. Ongoing research and development (R&D) activities to develop advanced technologies, as well as new product innovation, further creates numerous opportunities for the neurological biomarkers market share.

Recent Developments:

• In August 2020, Johnson & Johnson Services, Inc. has entered into a collaboration agreement with Enigma Biomedical Group to evaluate new neuroimaging biomarkers-JNJ-64413739 and JNJ-64511070-to better understand Alzheimer's disease and other dementias.
• In November 2021, Eisai Co. Ltd. and Biogen Inc. presented data on the use of plasma-based biomarkers in Phase 3 AHEAD 3-45 trial of lecanemab (BAN2401), an experimental anti-amyloid beta (A) protofibril antibody for Alzheimer's disease.
• In October 2021, Diadem announced the release of clinical data demonstrating that their AlzoSure biomarker test may forecast the course of Alzheimer's disease years before symptoms appear.
• In September 2020, Novartis Pharma AG and Siemens Healthineers inked a master cooperation agreement to invent, develop, and sell diagnostic tests for Novartis' pharmaceutical portfolio. The first program promotes the development of a serum NFL immunoassay to complement Novartis' MS and other neuroscience operations.

TOP MARKET PLAYERS OF THE NEUROLOGICAL BIOMARKERS MARKET

• Quanterix
• Qiagen
• ADx NeuroSciences NV
• Merck KGaA
• Enrolmmun
• Thermo Fisher Scientific
• ACOBIOM
• Banyan Biomarkers Inc.
• Olink Biosciences
• Bio-Rad Laboratories Inc.

Key Segments Profiled in the Neurological Biomarkers Market Survey

By Type:

• Genomics Biomarkers
• Proteomics Biomarkers
• Metabolomics Biomarkers
• Imaging Biomarkers
• Others

By Application:

• Alzheimer's Disease
• Parkinson's Disease
• Huntington's Disease
• Schizophrenia
• Depression
• Multiple Sclerosis
• Spinal Muscular Atrophy

By End User:

• Research Organizations
• Pharma & Biotech Companies
• Clinical Diagnostics

By Region:

• North America
• Latin America
• Asia Pacific
• Middle East and Africa (MEA)
• Europe